631-02-017 / 631-02-017 ISMRM Abstract

Spillover-, ssMT-, and T1-Corrected APTw MRI Improves the Distinction of IDH Status and 1p/19q Codeletion in Brain Gliomas

Primary: Contrast Mechanisms - CEST / APT / NOE

Secondary: Neuro - Tumors

631-02-017 · Everything About Contrast Mechanism · Thursday, 14 May, 1:40 PM–3:16 PM · Roof Terrace

Keywords: IDH mutation 1p 19q codeleted glioma Amide proton transfe weighted imaging Chemical exchange saturation transfer Fluid suppression

Accepted

Stefano Casagranda ¹, Capucine Cadin², Bertrand Mathon^2,3, Ottavia Dipasquale¹, Christos Papageorgakis¹, Mauro Zucchelli¹, Emmanuel Mandonnet^4,5, Stéphane Lehéricy^2,3, Marc Sanson^2,3, Patrick Liebig⁶, Moritz Zaiss⁷, Lucia Nichelli^2,3, Francesca Branzoli²

¹Innovation Lab, Olea Medical, La Ciotat, France

²Paris Brain Institute - ICM, INSERM U 1127, CNRS UMR 7225, Sorbonne University, Paris, France

³Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière-Charles-Foix, Paris, France

⁴Université de Paris Cité, Paris, France

⁵Department of Neurosurgery, Lariboisière Hospital, AP-HP, Paris, France

⁶Siemens Healthineers AG, Erlangen, Germany

⁷Department of Neuroradiology, Friedrich-Alexander Universität Erlangen-Nürnberg (FAU), Erlangen, Germany

Presenting Author: Stefano Casagranda

Synopsis

Motivation:

Goals:

Approach:

Results:

Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

References

1. J. Zhou, B. Lal, D. A. Wilson, J. Laterra, and P. C. M. van Zijl, ‘Amide proton transfer (APT) contrast for imaging of brain tumors’, Magnetic Resonance in Medicine, vol. 50, no. 6, pp. 1120–1126, 2003, doi: 10.1002/mrm.10651. [doi]

2. J. Zhou, J.-F. Payen, D. A. Wilson, R. J. Traystman, and P. C. M. van Zijl, ‘Using the amide proton signals of intracellular proteins and peptides to detect pH effects in MRI’, Nat Med, vol. 9, no. 8, pp. 1085–1090, Aug. 2003, doi: 10.1038/nm907. [doi]

3. J. Zhou et al., ‘Review and consensus recommendations on clinical APT ‐weighted imaging approaches at 3T : Application to brain tumors’, Magnetic Resonance in Med, vol. 88, no. 2, pp. 546–574, Aug. 2022, doi: 10.1002/mrm.29241. [doi]

4. S. Bisdas, E. Demetriou, C. C. Topriceanu, and Z. Zakrzewska, ‘The role of APT imaging in gliomas grading: A systematic review and meta-analysis’, European Journal of Radiology, vol. 133, p. 109353, Dec. 2020, doi: 10.1016/j.ejrad.2020.109353. [doi]

5. L. Nichelli , M. Zaiss, and S.Casagranda. 'APT weighted imaging in diffuse gliomas.' BJR| Open 5.1 (2023): 20230025, doi: 10.1259/bjro.20230025 [doi]

6. H. Heo, M. Singh, S. Z. Mahmud, L. Blair, D. O. Kamson, and J. Zhou, ‘Unraveling contributions to the Z‐spectrum signal at 3.5 ppm of human brain tumors’, Magnetic Resonance in Med, p. mrm.30241, Jul. 2024, doi: 10.1002/mrm.30241. [doi]

7. M. Zaiss et al., ‘Inverse Z-spectrum analysis for spillover-, MT-, and T1 -corrected steady-state pulsed CEST-MRI--application to pH-weighted MRI of acute stroke’, NMR Biomed, vol. 27, no. 3, pp. 240–252, Mar. 2014, doi: 10.1002/nbm.3054. [doi]

8. J.-R. Schüre et al., ‘Fluid suppression in amide proton transfer-weighted (APTw) CEST imaging: New theoretical insights and clinical benefits’, Magnetic Resonance in Medicine, vol. 91, no. 4, pp. 1354–1367, 2024, doi: 10.1002/mrm.29915. [doi]

9. Z. Turkalp, J. Karamchandani, and S. Das, ‘IDH mutation in glioma: new insights and promises for the future’, JAMA Neurol, vol. 71, no. 10, pp. 1319–1325, Oct. 2014, doi: 10.1001/jamaneurol.2014.1205. [doi]

10. D. N. Louis et al., ‘The 2021 WHO Classification of Tumors of the Central Nervous System: a summary’, Neuro Oncol, vol. 23, no. 8, pp. 1231–1251, Aug. 2021, doi: 10.1093/neuonc/noab106. [doi]

11. M. P. G. Broen et al., ‘The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower-grade glioma: a validation study’, Neuro Oncol, vol. 20, no. 10, pp. 1393–1399, Sep. 2018, doi: 10.1093/neuonc/noy048. [doi]

12. L. Mancini et al., ‘CEST MRI provides amide/amine surrogate biomarkers for treatment-naïve glioma sub-typing’, Eur J Nucl Med Mol Imaging, vol. 49, no. 7, pp. 2377–2391, Jun. 2022, doi: 10.1007/s00259-022-05676-1. [doi]

13. A. Deshmane, et al. '3D gradient echo snapshot CEST MRI with low power saturation for human studies at 3T.' Magnetic resonance in medicine 81.4 (2019): 2412-2423, doi: 10.1002/mrm.27569. [doi]

14. P. Schuenke et al. 'Simultaneous mapping of water shift and B1 (WASABI)—application to field‐inhomogeneity correction of CEST MRI data.' Magnetic resonance in medicine 77.2 (2017): 571-580, doi: 10.1002/mrm.26133. [doi]

15. S. Casagranda et al., ‘Principal Component selections and filtering by spatial information criteria for multi-acquisition CEST MRI denoising’, ISMRM, London, UK, p.2080, 2022, [Online]. Available: https://archive.ismrm.org/2022/2080.html

16. J. Buckheit et al., ‘About WaveLab’, Handbook of WaveLab Version 850, 1995, doi: 10.1007/978-1-4612-2544-7_5 . [doi]

17. S. Klein, M. Staring, K. Murphy, M. A. Viergever, and J. Pluim, ‘elastix: A Toolbox for Intensity-Based Medical Image Registration’, IEEE Trans. Med. Imaging, vol. 29, no. 1, pp. 196–205, Jan. 2010, doi: 10.1109/TMI.2009.2035616. [doi]

18. Wu, B., et al. "An overview of CEST MRI for non-MR physicists." EJNMMI physics 3.1 (2016): 19. doi: 10.1186/s40658-016-0155-2 [doi]

19. C. Papageorgakis et al., ‘Decorrelation Algorithm for Correcting B1 Artifacts in APTw Imaging at 3 Tesla’, ISMRM, Singapore, p.4469, 2024, [Online]. Available: https://archive.ismrm.org/2024/4469.html

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/631-02-017